ALMR Surges 35% as Street Lifts Targets Post-Earnings
Alamar Biosciences enters the week after its sharpest rally of the year, with a 35% gain forcing analysts to scramble and short sellers to reassess a position that looked comfortable just days ago. The catalyst is…
